Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Xiaoming Jia, Mahmoud Al Rifai, Anum Saeed, et al.
Vascular Health and Risk Management (2022) Vol. Volume 18, pp. 555-566
Open Access | Times Cited: 20

Showing 20 citing articles:

Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice
Giosiana Bosco, Francesco Barbagallo, Salvatore Spampinato, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 6, pp. 2444-2444
Open Access | Times Cited: 18
Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis
Kristina Zubielienė, Gintarė Valterytė, Neda Jonaitienė, et al.
Medicina (2022) Vol. 58, Iss. 11, pp. 1665-1665
Open Access | Times Cited: 27
Evaluating the role of PCSK9 inhibitors in reducing cardiovascular events among statin-intolerant patients: a systematic review and meta-analysis
Muhammad Farhan, Gamal Hussein, Thuraya Alom, et al.
Annals of Medicine and Surgery (2025) Vol. 87, Iss. 2, pp. 891-899
Open Access
Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan
Kuan-Chieh Tu, Wei‐Ting Chang, Hui-Wen Lin, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
New Oral PCSK9 Inhibitor: “MK-0616”
Zoya Siddiqui, William H. Frishman
Cardiology in Review (2024)
Closed Access | Times Cited: 3
The Efficacy of Tafolecimab in Chinese Patients with Hypercholesterolemia: A Systematic Review and Meta-analysis
Eeshal Fatima, Zaheer Qureshi, Mikail Khanzada, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 5, pp. 641-650
Closed Access | Times Cited: 3
Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies
Zaheer Qureshi, Mikail Khanzada, Adnan Safi, et al.
Annals of Medicine and Surgery (2024)
Open Access | Times Cited: 2
Role of Phytochemicals in Cardiovascular Disease Management: Insights into Mechanisms, Efficacy, and Clinical Application
Esther Ugo Alum
Phytomedicine Plus (2024), pp. 100695-100695
Open Access | Times Cited: 2
Disorders of Lipid Metabolism
Rushika Conroy, Stewart A. Mackie, Charlotte M. Boney
Pediatric Endocrinology (2024), pp. 859-887
Closed Access | Times Cited: 2
Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here
Melody Hermel, Madison Lieberman, Leandro Slipczuk, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 459-459
Open Access | Times Cited: 6
The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development
Michael H. Davidson, Andrew Hsieh, Mary R. Dicklin, et al.
JACC Basic to Translational Science (2024) Vol. 9, Iss. 8, pp. 1029-1040
Open Access | Times Cited: 1
Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies
Philip Branigan, Yen Duong, Ammar Abdulfattah, et al.
Cureus (2024)
Open Access | Times Cited: 1
Coronary Artery Calcification in Rheumatoid Arthritis Patients: A Systematic Review
Stephanie Nagy, Jordan Ditchek, Marc M Kesselman
Cureus (2024)
Open Access | Times Cited: 1
Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: A review of efficacy, safety, and outcomes
Moiud Mohyeldin, Ahmed S Abuelgasim, Ahmed Mg Mustafa
World Journal of Cardiology (2024) Vol. 16, Iss. 7, pp. 397-401
Open Access
Safety and efficacy of PCSK9 inhibitors and effect on coronary plaque phenotype in statin-treated patients following acute coronary syndrome: a systematic review and meta-analysis
Dennis Ievan Hakim, Faqrizal Ria Qhabibi, Muhammad Yusuf, et al.
The Egyptian Heart Journal (2024) Vol. 76, Iss. 1
Open Access
Roles of PCSK9 in the Pathogenesis of Periodontal Disease
Motahareh Khosrojerdi, Željko Reiner, Negin Vatanparast, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 39, pp. 6429-6435
Closed Access | Times Cited: 1
Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with Dyslipidaemia: A Population-Based Study
Oscar Hou In Chou, Lifang Li, Cheuk To Chung, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Endocrine Regulation of Microvascular Receptor—Mediated Transcytosis and Its Therapeutic Opportunities: Insights by PCSK9—Mediated Regulation
Alexander D. Mazura, Claus U. Pietrzik
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1268-1268
Open Access
Analysis of Adherence to anti-PCSK9 Antibody Therapy among Patients from Italy
Paolo Mongiello, R Petti, A Ciaccia, et al.
Cardiovascular & Haematological Disorders - Drug Targets (2023) Vol. 23, Iss. 2, pp. 111-121
Closed Access
Nuevos fármacos hipolipemiantes
Fernando Isidro Lago Deibe, Raquel del Río Rodríguez, Mabel Castro García, et al.
FMC - Formación Médica Continuada en Atención Primaria (2023) Vol. 30, Iss. 10, pp. 546-556
Closed Access
Page 1

Scroll to top